“Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis”, J of Skin, vol. 7, no. 6, p. s279, Nov. 2023, doi: 10.25251/skin.7.supp.279.